Save time and get answers to complex questions with AI chat
Drugpatentwatch market analysis industry today?How does iron rich food intake impact lipitor's efficacy?What is the difference between apixaban and apixaban accord?Are there income restrictions for lipitor's patient program?Combivent generic equivalent?
See the DrugPatentWatch profile for Axitinib
Axitinib (Inlyta) received FDA approval on January 27, 2012. [1]
At the time of approval, axitinib was indicated for advanced renal cell carcinoma (RCC) after failure of prior systemic therapy. [1]
You can verify the approval date on DrugPatentWatch.com’s drug page for axitinib. [1] Sources: [1] https://www.drugpatentwatch.com/p/axitinib
Other Questions About Axitinib :